ŽOURKOVÁ, Alexandra, Eva HADAŠOVÁ, Marie TOMANDLOVÁ and Miroslav ROBEŠ. Klinický význam CYP 2D6 v průběhu léčby novějšími antidepresivy /Abstrakt/ (Clinical impact of CYP2D6 during treatment with newer antidepressants /Abstract/). Psychiatrie. Praha: TIGIS, 2002, vol. 6, Suppl. 1, p. 46. ISSN 1211-7579.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Klinický význam CYP 2D6 v průběhu léčby novějšími antidepresivy /Abstrakt/
Name (in English) Clinical impact of CYP2D6 during treatment with newer antidepressants /Abstract/
Authors ŽOURKOVÁ, Alexandra (203 Czech Republic, guarantor), Eva HADAŠOVÁ (203 Czech Republic), Marie TOMANDLOVÁ (203 Czech Republic) and Miroslav ROBEŠ (203 Czech Republic).
Edition Psychiatrie, Praha, TIGIS, 2002, 1211-7579.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30000 3. Medical and Health Sciences
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/02:00006073
Organization unit Faculty of Medicine
Keywords in English CYP2D6; Antidepressants; Paroxetine; Mirtazapine;
Tags antidepressants, CYP2D6, Mirtazapine, paroxetine
Tags International impact
Changed by Changed by: prof. MUDr. Alexandra Žourková, CSc., učo 81. Changed: 25/11/2006 10:12.
Abstract
Cílem studie bylo sledování vlivu dlouhodobé léčby paroxetinem a mirtazapinem na aktivitu CYP2D6 se zaměřením na průběh odeznívání inhibice navozené paroxetinem. Nalezené změny CYP2D6 byly korelovány s výskytem nežádoucích účinků léčby.
Abstract (in English)
Aim of the study was to follow the influence of a long-term therapy with paroxetine and mirtazapine on the CYP2D6 activity with a special attention focused on the course of dying away of the enzyme inhibition induced by paroxetine. The found-out changes were correlated with the occurence of the adverse effects of treatment.
PrintDisplayed: 31/8/2024 06:10